NVAX Holds Its Ground as Bears Dig Back In

Novavax finds itself in an odd position this week: the stock is up 13% and bears are still running the show.

The plague-scare rally that drove a 20% single-day gain on October 5 has largely held this time, unlike the pattern described in the note filed Wednesday October 8, when the stock was fading back toward $11.22. The close on October 13 was $12.82, up 13.3% on the week and 36% over the past month. That is a material change from what the mid-week note observed. The catalyst remains the same external scare rather than anything company-specific, but the market's willingness to hold the gains is the new data point.

Short interest has eased slightly but remains one of the more crowded positions in mid-cap biotech. ORTEX estimates 45.9 million shares short as of October 13, equivalent to 28.2% of the free float. That is down about 1.8% on the week and off from the mid-September peak above 48 million shares, but it is still among the highest short positions in the sector. The previous note flagged bears reloading after the squeeze. That rebuilding has now partially reversed again, with the short count falling from 47.2 million on October 8 back to current levels. FINRA's official fortnightly count pegs days to cover at 8.1 on 46 million shares, consistent with the ORTEX estimate. Borrow costs have eased alongside: the cost to borrow has fallen 14% on the week to 0.69%, well below the late-September readings above 1%. Availability, however, has tightened sharply. The ratio of shares still available to borrow relative to shares already borrowed has dropped to 29.3%, half of where it was mid-week when the prior note was filed and well below the 60% available on October 7. For a stock that touched near-zero availability in mid-September, this tightening is worth watching. Any renewed buying pressure has less cushion in the lending pool than it did a week ago.

Options traders are not reading this as an extreme moment in either direction. The put/call ratio is 0.58, almost exactly in line with its 20-day average of 0.575, and the z-score of 0.13 points to a market that is broadly neutral on near-term direction. That calm sits in contrast to the short book: with nearly three in ten free-float shares sold short, you would expect more defensive positioning. The PCR has traded in a range of 0.38 to 0.71 over the past year, and the current reading is squarely in the middle, suggesting the options market has not materially repriced the risk that bears see.

The Street is divided and the analyst data is mixed in vintage. BTIG maintains a Buy with a $19 target, HC Wainwright has a Buy at $16, and Cantor Fitzgerald initiated at Overweight with an $18 target in late October 2025. On the other side, JPMorgan carries an Underweight with a $6 target, last updated in November 2025. The mean target across the panel is $14.11, implying modest upside from the current $12.82 price, though several of these targets date from six months ago or earlier and should be treated cautiously. The bull case centres on the Matrix-M adjuvant platform and the Sanofi collaboration as a path to royalty income beyond the COVID booster franchise. The bear case is blunter: surveyed physicians expected an 11% decline in US COVID-19 boosters for the 2026-27 season, and IQVIA data already showed roughly a 26% drop in prescriptions through late 2025. The ORTEX short score has eased from 81 a week ago to 78.4, still placing Novavax in the 4th percentile of the market on this rank, meaning almost every other stock has a less bearish short profile.

One ownership detail sharpens the context. Himanshu H. Shah filed a Schedule 13D activist disclosure, first lodged in October 2025 and amended most recently in May 2026, reporting a 9.03% stake. A 13D filing signals active intent rather than passive holding, and Shah Capital Management appears in the institutional register with a reported 7.4% position as of September 30, increased by 1.35 million shares in the period. BlackRock and State Street also hold above 7% each, and Sanofi sits on the register at 4.2% as a strategic partner. These are sizeable institutional anchors for a stock with this level of short interest. Stakes are as last disclosed around the 5% threshold, and holders can fall below that level without filing again.

Earnings land on November 9, 26 days away. The last print, August 6, produced a 3.2% one-day gain and a 5.7% five-day gain, though that was a single event against a very different backdrop. With availability tightening again, short interest still at 28% of the float, an activist on the register, and the market holding a rally that had every reason to fade, the question heading into the print is whether the lending market tightens further before November 9 or whether bears use the remaining cushion to reload once more.